

## METHODS

### Study population

Fourteen patients (8 male and 6 female patients; age range, 20-54 years) were classified as having mild persistent asthma on the basis of clinical history and pulmonary function studies.<sup>E1</sup> All patients were atopic as documented by a positive skin test result for at least 1 aeroallergen. Inhaled corticosteroids were discontinued at least 4 weeks before bronchoscopy, and only short-acting  $\beta_2$ -agonists on demand were allowed. As a control group, we enrolled patients (14 male and 5 female patients; age range, 18-60 years) with a single lung lesion in whom the BALF used for the experiments was obtained from the contralateral side. They had no history of atopic diseases and at the time of bronchoscopy were free of respiratory symptoms and had forced vital capacity and FEV<sub>1</sub> values of greater than 90% of the predicted value.

### Bronchoalveolar lavage procedure

A flexible fiberoptic bronchoscope (Olympus BF type P20; Olympus, Center Valley, Pa) was wedged into a segmental or subsegmental bronchus, and 3 fractions (50 mL each) of saline preheated at 37°C were introduced. Recovered fluid was pooled and filtered through 2 layers of sterile gauze. The fluid was then centrifuged twice at 800g for 10 minutes at 4°C and stored at -80°C for determination of PLA<sub>2</sub> activity and total protein content by a Bradford-based assay (Bio-Rad, Hercules, Calif).

### Purification of human lung mast cells

Lung fragments chopped with scissors were dispersed into their cellular elements by means of enzymatic digestion with pronase (Calbiochem, San Diego, Calif), chymopapain (Sigma), collagenase, and elastase (Calbiochem). The mast cell suspension was enriched (>80%) by means of flotation over Percoll (Sigma) density gradients and then purified by using positive immunomagnetic selection with the CD117 Microbead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Mast cell numbers and purity were determined

by means of toluidine blue staining. The purity of mast cells used in the experiments was always greater than 98%.


### RT-PCR

For semiquantitative PCR, equivalent templates of cDNAs were amplified by using target-specific primers for hGIB, hGIIA, hGIID, hGIII, hGIIF, hGIII, hGV, hGX, hGXIIA, hGXIIIB, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; see Table E1). The PCR products were separated on 2% agarose gel, stained with ethidium bromide, and visualized by using the image analysis system ChemidocXRS (Bio-Rad).

Real-time quantitative PCR (qPCR) was performed on the iCycler (Bio-Rad) with the Platinum SYBR Green qPCR kit (Invitrogen). Target-specific primers for hGIIA, hGIID, hGIII, hGIIF, hGIII, hGV, hGX, and GAPDH suitable for qPCR were designed by using the Beacon Designer 3.0 (Bio-Rad; see Table E1). After an initial denaturation step at 94°C for 30 seconds, amplification was performed with 40 cycles of denaturation (94°C) for 30 seconds, annealing (55°C) for 30 seconds, and primer extension (72°C). The data were analyzed with iCycler iQ analysis software (Bio-Rad), and the mRNA signals in each sample were normalized to that of the GAPDH mRNA. The quantification of the mRNA target was obtained by calculating the relative expression of the reference gene compared with GAPDH. Data were expressed as  $\Delta$  cycle threshold (Ct), which was calculated as the number of PCR cycles for liftoff for the target mRNA of interest minus the number of PCR cycles for liftoff for GAPDH mRNA:  $\Delta$ Ct = Ct (gene of interest) - Ct (GAPDH). The Ct values for GAPDH were typically around 23. A  $\Delta$ Ct of less than 10 means high to medium expression, a  $\Delta$ Ct of 10 to 15 means medium to low expression, and a  $\Delta$ Ct of greater than 15 means low expression.

### REFERENCE

- E1. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007. *J Allergy Clin Immunol* 2007;120(suppl): S94-S138.



**FIG E1.** Correlation between PLA<sub>2</sub> activity and protein content in the BALF. Cell-free BALF from patients with bronchial asthma (**A**; n = 14) and control subjects (**B**; n = 19) was assayed for PLA<sub>2</sub> activity by using tritiated OA-labeled *E coli* membranes, as described in the Methods section, and for total protein content by using a Bradford-based assay. Data are plotted as a function of PLA<sub>2</sub> activity versus protein content. Correlation was assessed by using the linear regression function of Microsoft Excel software.

**TABLE E1.** Primer sequences and conditions for RT-PCR and qPCR

Target*	Product length (bp)	Ta	Primer (5'-3')	GenBank accession no. or reference
hGIB (RT-PCR)	341	60°C	Forward: TCCTTGCTAGCTGTGCTG Reverse: TGAAGCCTCACACTCTTTG	Degousee et al <sup>24</sup>
hGIIA (RT-PCR)	434	57°C	Forward: ATGAAGACCCTCCTACTGTT Reverse: TCAGCAACGAGGGGTGCTCC	Degousee et al <sup>24</sup>
hGIIA (qPCR)	117	55°C	Forward: ACCCTCCCTCCCTACCCTAAC Reverse: AATCTGCTGGATGTCTCATTCTGG	NM_000300
hGIID (RT-PCR)	294	60°C	Forward: GAAAATGCCCATCCTCTCCT Reverse: AAACGCAGTCGCTTCTGGTA	Degousee et al <sup>24</sup>
hGIID (qPCR)	85	55°C	Forward: CGGACTAGGTGGCAGAGG Reverse: GGTCTTCAGGTGGTCATAGC	NM_012400
hGIII (qPCR)	120	53°C	Forward: GGTGTTCTTTGCTCCTG Reverse: CCGCAGTAACAGCCATAGTC	NM_014589
hGIIF (qPCR)	211	55°C	Forward: GACCCACACCCTCTCTCC Reverse: GATGCTCTCCCTGCTTACG	NM_0221819
hGIII (RT-PCR)	500	60°C	Forward: TGCCTACAGAATCAGCACGA Reverse: TTGAGCAGCTGGAACCTCGAT	Degousee et al <sup>24</sup>
hGIII (qPCR)	100	55°C	Forward: GCGAGCAGCAGGGCAGAG Reverse: AGAATCTCCAACCTCCACACCACAG	NM_015715
hGV (RT-PCR)	358	60°C	Forward: TTGGTTCCTGGCTGTAGTGTG Reverse: TGGGTTGTAGCTCCGTAGGTTT	Degousee et al <sup>24</sup>
hGV (qPCR)	100	55°C	Forward: GCAACATTGCGCACACAGTCC Reverse: CGGTCACAGGCACAGAGG	NM_000929
hGX (RT-PCR)	370	60°C	Forward: GATCCTGGAACCTGGCAGGAA Reverse: TCAGTCACACTTGGGCGAGT	Degousee et al <sup>24</sup>
hGX (qPCR)	94	55°	Forward: GCTGCTGCTGCTTCTACC Reverse: CACAGTTCCTGCCAGTTCC	NM_003561
hGXIIA (RT-PCR)	105	55°C	Forward: TGTTGTCAGGTGCCAGGAG Reverse: AAGGCGCGTTCAGGTAC	BC_017218
hGXIIIB (RT-PCR)	115	55°C	Forward: GCCTGTGATTCCCTGGTTGAC Reverse: ACTCTTCCTTCTCCTCCTCTGC	NM_032562
GAPDH (qPCR)	141	55°C	Forward: GTCCACTGGCGTCTTCAC Reverse: CTTGAGGCTGTTGCATACCTC	Granata et al <sup>30</sup>

\*For PLA<sub>2</sub>s, *h* stands for human, the Roman number after the letter G indicates the group, and the letter in caps after the number indicates the subgroup (eg, hGIB indicates human group IB PLA<sub>2</sub>s).

Ta, Annealing temperature.